Extending hypofractionated stereotactic body radiotherapy to tumours larger than 70cc - effects and side effects.
SBRT
Stereotactic
hypofractionation
Journal
Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: England
ID NLM: 8709065
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
pubmed:
16
1
2021
medline:
19
8
2021
entrez:
15
1
2021
Statut:
ppublish
Résumé
Stereotactic body radiotherapy (SBRT) for tumours ≥5 cm is poorly studied and its utility and feasibility is uncertain. We here report the Karolinska experience of SBRT in this setting. All patients had a gross tumour volume (GTV) ≥70 cc, a prescribed physical dose of at least 40 Gy and received treatment between 1995-2012. We included 164 patients with 175 tumours located in the thorax ( SBRT of tumours >5 cm in diameter may be an option for peripherally located lung and abdominal tumours. Histological origin and tumour location should be considered before treatment.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Stereotactic body radiotherapy (SBRT) for tumours ≥5 cm is poorly studied and its utility and feasibility is uncertain. We here report the Karolinska experience of SBRT in this setting.
MATERIAL AND METHODS
METHODS
All patients had a gross tumour volume (GTV) ≥70 cc, a prescribed physical dose of at least 40 Gy and received treatment between 1995-2012.
RESULTS
RESULTS
We included 164 patients with 175 tumours located in the thorax (
CONCLUSION
CONCLUSIONS
SBRT of tumours >5 cm in diameter may be an option for peripherally located lung and abdominal tumours. Histological origin and tumour location should be considered before treatment.
Identifiants
pubmed: 33448899
doi: 10.1080/0284186X.2020.1866776
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM